Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action due to allegations of making false or misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines following study failures [1][2] Summary by Relevant Sections Company Overview - Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is under investigation by Faruqi & Faruqi, LLP for potential securities law violations related to its clinical trials [1] Allegations - The complaint alleges that Ultragenyx and its executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived efficacy of the treatment [1] Stock Performance - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [2] Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is April 6, 2026 [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [2]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [1] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [1] Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until April 6, 2026, to request to be appointed as lead plaintiff in the lawsuit [1] - Class members may be entitled to compensation without any out-of-pocket costs or fees [1] - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [1]

Core Viewpoint - Gilead Sciences Inc. reported strong fourth-quarter earnings but provided weak guidance for fiscal 2026, leading to a decline in share price [1][2]. Financial Performance - Gilead reported quarterly earnings of $1.86 per share, exceeding the consensus estimate of $1.81 [1]. - Quarterly revenue reached $7.93 billion, surpassing the Street estimate of $7.69 billion [1]. Future Guidance - For fiscal 2026, Gilead expects adjusted EPS in the range of $8.45 to $8.85, compared to the analyst estimate of $8.74 [2]. - Revenue guidance for fiscal 2026 is projected between $29.6 billion and $30 billion, below the analyst estimate of $30.22 billion [2]. Analyst Ratings and Price Targets - Needham analyst Joseph Stringer maintained a Buy rating and raised the price target from $140 to $170 [4]. - Scotiabank analyst Louis Chen maintained a Sector Outperform rating and increased the price target from $140 to $177 [4]. - Cantor Fitzgerald analyst Carter Gould maintained an Overweight rating and raised the price target from $135 to $155 [4]. Market Reaction - Following the earnings announcement and guidance, Gilead shares fell 1.8% to $144.55 in pre-market trading [2].

Core Viewpoint - Deutsche Bank has reduced its price target for Novo Nordisk by 16% to DKK400, citing revenue challenges, management uncertainty, and clinical trial risks [1]. Group 1: Financial Performance and Projections - The analyst warned of a "double-digit revenue decline" for Novo Nordisk in the current year, although the stock is trading at a "mid-teens price-to-earnings ratio" [2]. - The launch of an oral obesity treatment and potential demand recovery in the second half of the year may support the stock [2]. Group 2: Management and Business Environment - The current management situation is described as fluid, with limited business visibility and a clear downside scenario [3]. - Data from clinical trials of CagriSema, a key obesity treatment candidate, will be critical for future performance [3]. Group 3: Market Reaction - Following the announcement, Novo Nordisk shares fell by 2.4% to DKK307.55 [3]. - Despite the target cut, Deutsche Bank maintained a 'buy' rating on the stock [3].

Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two Australian sites already open and recruiting patients Three additional US sites are expected to be open in the coming weeks Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that two (2) sites in the US have been initiated and will shortly be commencing recruitment activi ...

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has participated in the national centralized procurement for drugs whose agreements are expiring, with some products expected to be selected for procurement [1] Group 1: Procurement Participation - Zhejiang Beid Pharmaceutical has submitted applications for the national centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement selection were published by the procurement office on February 10, 2026, indicating that some products from Beid Pharmaceutical are likely to be selected [1] Group 2: Selected Products and Financial Impact - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets, both of which are included in the national medical insurance catalog [1] - For the year 2024, the sales revenue of Clarithromycin tablets is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue of Simvastatin tablets is projected to be 1.71 million yuan, representing 0.52% of the company's main business income during the same period [1]

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]

Market Overview - US equity futures are flat, with S&P and Nasdaq 100 futures both up 0.1% as the market anticipates weaker payroll data following a Retail Sales miss and weaker high-frequency data [1] - International markets show mixed trends, with Japan closed, KOSPI up 1%, and HSI up 0.3%, while European markets are mostly flat to down [1] - Commodities are moving higher, led by silver, with crude oil prices quietly rising [1] Company Performance - In premarket trading, Mag 7 stocks are mixed, with Nvidia up 0.6% and Tesla down 0.2% [3] - Astera Labs falls 11% after reporting disappointing fourth-quarter results and announcing the retirement of its CFO [3] - Beta Technologies climbs 18% after Amazon disclosed a stake in the electric aircraft manufacturer [3] - Centrus Energy falls 8% as its fourth-quarter earnings per share missed analyst estimates due to higher-than-expected capex spending [3] - Cloudflare gains 14% after beating fourth-quarter expectations and providing a bullish revenue forecast [3] - Humana falls 6% after forecasting full-year profit below Wall Street expectations, raising concerns about the US health-insurance industry [3] - Kraft Heinz drops 6% after pausing its planned separation as the new CEO seeks to improve results [3] - Lyft falls 17% after issuing a disappointing forecast that missed Wall Street expectations [3] - Mattel slumps 26% after its 2026 adjusted earnings-per-share forecast missed analyst estimates, leading to a downgrade at JPMorgan [3] - Moderna falls 10% after US regulators refused to review its novel mRNA flu vaccine [3] - Rapid7 declines 22% after a disappointing outlook, with analysts citing weakness in annual recurring revenue [3] Earnings Reports - Out of 326 S&P 500 companies that have reported, 78% have beaten analyst forecasts, while 17% have missed [11] - T-Mobile, Shopify, and Kraft Heinz are among companies expected to report before the market opens [11] Economic Indicators - Analysts expect January's payrolls report to show 65,000 job additions, with a whisper number of 35,000, amid expectations of a significant downward revision of 750,000 to 900,000 jobs through March 2025 [4][25] - The unemployment rate is expected to remain steady at 4.4% [25] - The market is currently pricing in two or three Fed rate cuts this year, with a growing probability of a cut by April [5][38]

Core Viewpoint - The article discusses the significant environmental and manufacturing challenges posed by GLP-1 peptide drugs, particularly focusing on the solvent consumption and waste generation associated with the mainstream solid-phase peptide synthesis (SPPS) process, which could lead to increased costs and regulatory pressures in the industry [5][7][9]. Group 1: Manufacturing Process Issues - The industrial synthesis of peptide drugs has long relied on SPPS, which, while mature and suitable for commercialization, has high solvent consumption and waste generation [7]. - The SPPS process requires extensive washing steps to remove unreacted materials and by-products, leading to substantial solvent usage and hazardous waste production [7]. - The environmental concerns surrounding GLP-1 drugs stem from the inherent high waste generation of the mainstream manufacturing process rather than the drugs themselves [7]. Group 2: Impact of Increased Demand - GLP-1 drugs are unique in that they have reached unprecedented scales of demand, which amplifies the manufacturing externalities that were previously manageable [8]. - The solvent intensity per kilogram of GLP-1 API is significantly higher than that of typical small-molecule drugs, leading to increased costs for solvent procurement, recovery systems, and hazardous waste disposal [8]. - The scale of waste generated, potentially reaching "tens of millions of kilograms," elevates the issue from a technical detail to an industry-wide concern, affecting new capacity approvals and supply chain logistics [8]. Group 3: Regulatory and Cost Implications - The tightening of regulations around solvents like DMF is leading to increased long-term costs for companies, including higher disposal costs and the need for ongoing capital expenditures for waste management facilities [9][10]. - Compliance risks are also rising, as any incidents related to emissions or waste management can result in significant penalties and operational disruptions [10]. - The differences in manufacturing costs across regions are increasingly driven by regulatory environments rather than labor costs, highlighting the importance of compliance in the overall cost structure [10].

Core Viewpoint - Gilead expects its HIV portfolio sales to grow by 6% in 2026, driven by the recently launched PrEP drug Yeztugo, despite facing some headwinds from regulatory agreements and market conditions [1][2][6] Sales Performance - Gilead's HIV drugs generated $20.8 billion in sales for the full year 2025, marking a 6% increase from 2024, primarily due to the strong performance of Biktarvy, which saw sales rise by 7% to $14.3 billion [1][4] - The company anticipates total product sales between $29.6 billion and $30 billion in 2026, factoring in a decline in demand for Veklury, a Covid-19 antiviral [5] Yeztugo's Impact - Yeztugo, a biannual PrEP option, achieved $150 million in sales in 2025 after its FDA approval in June, with expectations to reach $800 million in 2026, representing a 433% year-over-year growth [3][6] - Analysts from Citi believe that the sales target for Yeztugo is achievable, indicating strong market potential [3] Future Projections - GlobalData forecasts that Yeztugo will continue to grow, potentially reaching $5.34 billion in annual sales by 2031, supported by ongoing demand for HIV prevention [4] - Gilead's CEO emphasized the company's secure business outlook, with no major loss of exclusivities until 2036, suggesting a stable growth trajectory [6]